http://www.fda.gov/cder/orange/appendix_a.txt 400, ERYTHROMYCIN ETHYLSUCCINATE E.E.S., ERYTHROMYCIN ETHYLSUCCINATE EC-NAPROSYN, NAPROXEN ECONAZOLE NITRATE, ECONAZOLE NITRATE ECONOCHLOR, CHLORAMPHENICOL ECONOPRED PLUS, PREDNISOLONE ACETATE ECONOPRED, PREDNISOLONE ACETATE EDECRIN, ETHACRYNATE SODIUM EDECRIN, ETHACRYNIC ACID EDETATE DISODIUM, EDETATE DISODIUM EDEX, ALPROSTADIL EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM...
Drug Approvals for May 1997 Drug Approvals for May 1997 Definitions and Notes May 1997 Original New Drug Applications Original Application #: 020497 Approval Date: 29-MAY-97 Trade Name: FARESTON Chemical Type: 1 Therapeutic Potential: S Dosage Form: TABLET Applicant: ORION CORP Active Ingredient(s): TOREMIFENE CITRATE OTC/RX Status: RX Indication(s): Treatment of metastatic breast cancer in...
DDPA January 1996 20-454 ZANTAC 150 GLAXO WELLCOME RANITIDINE HYDROCHLORIDE 02-JAN-96 (TABLET, CHEWABLE) RES TRIANGLE PK, NC EQ 150MG BASE 27709 (HISTAMINE H-2 RECEPTOR ANTAGONIST) 20-497 FARESTON ORION TOREMIFENE CITRATE 03-JAN-96 (TABLET) ESPOO, FINLAND EQ 60MG BASE (NONSTEROIDAL ANTIESTROGEN) 20-552 COVERA-HS SEARLE VERAPAMIL HYDROCHLORIDE 17-JAN-96 (TABLET, SKOKIE, IL 180MG...
Drug Approvals October 1996 Drug Approvals for October 1996 Definitions and Notes October 1996 Original New Drug Applications Original Application #: 019821 Approval Date: 28-OCT-96 Trade Name: SORIATANE Chemical Type: 2 Therapeutic Potential: S Dosage Form: CAPSULE Applicant: HOFFMAN-LAROCHE Active Ingredient(s): ACITRETIN OTC/RX Status: RX Indication(s): Treatment of severe psoriasis Original Application #:...
Drug Approvals for November 1997 Drug Approvals for November 1997 Definitions and Notes November 1997 Original New Drug Applications Original Application #: 020652 Approval Date: 26-NOV-97 Trade Name: TESLASCAN Chemical Type: 1 Therapeutic Potential: S Dosage Form: INJECTABLE Applicant: NYCOMED INC Active Ingredient(s): MANGAFODIPIR TRISODIUM OTC/RX Status: RX Indication(s): As an adjunct to MRI to enhance the T1...
http://www.signalgene.com/press_releases/01_11_07FINAL.pdf page 2
http://www.emea.eu.int/pdfs/human/press/pr/017996en.pdf The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit 7, Westferry Circus, Canary Wharf, London E14 4HB, UK Switchboard: (+ 44- 171) 418 84 00 Fax: (+ 44- 171) 418 85 51 London, 15 February 1996 CPMP/ 179/ 96 PRESS RELEASE The Committee for Proprietary Medicinal ...
author: Jerry Wells
http://www.emea.eu.int/pdfs/human/press/pr/017996en.pdf page 1 The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit 7, Westferry Circus, Canary Wharf, London E14 4HB, UK Switchboard: (+ 44- 171) 418 84 00 Fax: (+ 44- 171) 418 85 51 London, 15 February 1996 CPMP/ 179/ 96 PRESS RELEASE The Committee for Proprietary Medicinal ...
author: Jerry Wells
http://www.emea.eu.int/pdfs/human/press/pr/051396en.pdf The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Switchboard: (+ 44- 171) 418 8400 Fax: (+ 44- 171) 418 8551 E_ Mail: mail@ emea. eudra. org http:// www. eudra. org/ emea. html London, 20 June 1996 CPMP/ ...
author: Jerry Wells
http://www.emea.eu.int/pdfs/human/press/pr/051396en.pdf page 4 Doc. Reference: CPMP/ 513/ 96 12 June 1996 Page 4/ 4 Product a) Brandname b) INN c) List A/ B Company a) Name b) Origin Therapeutic Area a) ATC b) Indication Presentation a) Form b) Dose c) Number of Presentations EMEA/ CPMP a) Validation b) Opinion c) Active Time d) Clock stop Commission a) Date of decision ...
author: Jerry Wells
http://www.emea.eu.int/pdfs/human/press/pr/064496en.pdf The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Switchboard: (+ 44- 171) 418 8400 Fax: (+ 44- 171) 418 8551 E_ Mail: mail@ emea. eudra. org http:// www. eudra. org/ emea. html London, 18 July 1996 CPMP/ ...
author: Jerry Wells
http://www.emea.eu.int/pdfs/human/press/pr/064496en.pdf page 4 Product a) Brandname b) INN c) List A/ B Company a) Name b) Origin Therapeutic Area a) ATC b) Indication Presentation a) Form b) Dose c) Number of Presentations EMEA/ CPMP a) Validation b) Opinion c) Active Time d) Clock stop Commission a) Date of decision b) OJ No. a) Fareston b) Toremifene c) List B a) ...
author: Jerry Wells
IROA - Scientific Study Reference Search RU26752 RU-28318 RU-486 S3226 Saquinavir Serotonin Sildenafil Sildenafil Citrate Sodium Acetylsalicylic Acid Sodium Arsenite Spironolactone ss-Carotene ss-Estradiol 3-Benzoate Stanozolol Strychnine Synthroid Tamoxifen Tamoxifen (4-Hydroxy) Tamoxifen (Free Base) Tamoxifen Citrate Tamoxifen Methiodide Tamoxifin Testosterone Testosterone Acetate Testosterone Cypionate...
Custom Pellets Published by Cemagref: 389-400 (1991) MANUMYCIN: Journal of Clinical Endocrinology & Metabolism, 86(4): 1769-1777 (2001) 1-METHYL-DL-TRYPTOPHAN: Nature Immunology 2(1):64-68 (2001) Science, 281: 1191-1193 (1998) Nature Immunology, Advance Online Publication, September 30, 2002 NANDROLONE DECANOATE: Journal of Applied Physiology, 63(5): 2122-2127 (1987) Journal of Applied Physiology,...
http://www.fda.gov/cder/dmf/text/4Q2003ACTIVETYPE2TEXT.txt 2900 06-Apr-77 AVENTIS PHARMA SA HYDROCORTISONE HEMISUCCINATE 2904 13-Apr-77 ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV ERTHROMYCIN PHOSPHATE 2911 12-Apr-77 ORGAMOL SA BUPIVACAINE HCL 2922 02-May-77 AVENTIS PHARMA SA 6-ALPHA-METHYLPREDNISOLONE HEMISUCCINATE 2938 09-May-77 PROCOS SPA PHENYLTOLOXAMINE CITRATE 2942 09-May-77 PROCOS SPA ORPHENADRINE HYROCHLORIDE & ORPHENADRINE...
http://www.fda.gov/cder/dmf/xls/4Q2003ACTIVETYPE2EXCEL.xls AVENTIS PHARMA SA HYDROCORTISONE HEMISUCCINATE ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV ERTHROMYCIN PHOSPHATE ORGAMOL SA BUPIVACAINE HCL AVENTIS PHARMA SA 6-ALPHA-METHYLPREDNISOLONE HEMISUCCINATE PROCOS SPA PHENYLTOLOXAMINE CITRATE PROCOS SPA ORPHENADRINE HYROCHLORIDE & ORPHENADRINE CITRATE BASF CORP POVIDONE-IODINE LEK PHARMACEUTICALS D.D
